A Clinical Study to Evaluate TPM501 for Treatment of Celiac Disease
Latest Information Update: 26 Oct 2020
At a glance
- Drugs TPM 501 (Primary)
- Indications Coeliac disease
- Focus Adverse reactions
- Sponsors Topas Therapeutics
- 26 Oct 2020 New trial record
- 19 Oct 2020 According to a Topas Therapeutics media release, TPM501 is progressing towards clinic for treatment of celiac disease.